ReviewOncoimmunology2015
Trial Watch: Adoptive cell transfer for oncological indications.
Open access · goldAbstract readReview
In one paragraph
Review in Oncoimmunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.9field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 32 citations in OpenAlex.
- Selection, engineering, and in vivo testing of a human leukocyte antigen-independent T-cell receptor recognizing human mesothelin.PloS one · 2024Article
- CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy.Biomolecules · 2023Review
- Fibroblasts Impair Migration and Antitumor Activity of NK-92 Lymphocytes in a Melanoma-on-Chip Model.Bioengineering (Basel, Switzerland) · 2022Article
- Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer.Frontiers in immunology · 2022Review
- Comparison of Three CD3-Specific Separation Methods Leading to Labeled and Label-Free T Cells.Cells · 2021Article
- Trial watch: intratumoral immunotherapy.Oncoimmunology · 2021Review
- Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia.Medical oncology (Northwood, London, England) · 2020Review
- Dinutuximab Synergistically Enhances the Cytotoxicity of Natural Killer Cells to Retinoblastoma Through the Perforin-Granzyme B Pathway.OncoTargets and therapy · 2020Article
- Solid Tumors Challenges and New Insights of CAR T Cell Engineering.Stem cell reviews and reports · 2019Review
- Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Combination therapy: A feasibility strategy for CAR-T cell therapy in the treatment of solid tumors.Oncology letters · 2018Review
- An ultrastructural investigation of tumors undergoing regression mediated by immunotherapy.Oncotarget · 2017Article
- Cytokine-induced killer cells hunt individual cancer cells in droves in a mouse model.Cancer immunology, immunotherapy : CII · 2017Article
- Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches.Frontiers in oncology · 2017Review
- Immunological effects of a novel RNA-based adjuvant in liver cancer patients.Cancer immunology, immunotherapy : CII · 2017Article
- Adoptive Transfer of Tracer-Alloreactive CD4American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2016Article
- Chemotherapy and radiation therapy elicits tumor specific T cell responses in a breast cancer patient.BMC cancer · 2016Article
- Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies.Oncoimmunology · 2016Article
- CAR T Cell Therapy: A Game Changer in Cancer Treatment.Journal of immunology research · 2016Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 9 institutions in 5 countries.
Fernando ArandaGroup of Immune Receptors of the Innate and Adaptive System; Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS) ; Barcelona, Spain.
Aitziber BuquéGustave Roussy Cancer Campus ; Villejuif, France ; INSERM; U1138 ; Paris, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Centre de Recherche des Cordeliers ; Paris, France.
Norma BloyGustave Roussy Cancer Campus ; Villejuif, France ; INSERM; U1138 ; Paris, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Centre de Recherche des Cordeliers ; Paris, France.
Francesca CastoldiINSERM; U1138 ; Paris, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Centre de Recherche des Cordeliers ; Paris, France ; Faculté de Medicine; Université Paris Sud/Paris XI ; Le Kremlin-Bicêtre, France ; Sotio a.c. ; Prague, Czech Republic.
Alexander EggermontGustave Roussy Cancer Campus ; Villejuif, France.
Isabelle CremerINSERM; U1138 ; Paris, France ; Equipe 13; Centre de Recherche des Cordeliers ; Paris, France ; Université Pierre et Marie Curie/Paris VI ; Paris, France.
Wolf Hervé FridmanINSERM; U1138 ; Paris, France ; Equipe 13; Centre de Recherche des Cordeliers ; Paris, France ; Université Pierre et Marie Curie/Paris VI ; Paris, France.
Jitka FucikovaSotio a.c. ; Prague, Czech Republic ; Dept. of Immunology; 2nd Faculty of Medicine and University Hospital Motol; Charles University ; Prague, Czech Republic.
Jérôme GalonINSERM; U1138 ; Paris, France ; Université Pierre et Marie Curie/Paris VI ; Paris, France ; Laboratory of Integrative Cancer Immunology; Centre de Recherche des Cordeliers ; Paris, France ; Université Paris Descartes/Paris V , Sorbonne Paris Cité , Paris, France.
Radek SpisekSotio a.c. ; Prague, Czech Republic ; Dept. of Immunology; 2nd Faculty of Medicine and University Hospital Motol; Charles University ; Prague, Czech Republic.
Eric TartourUniversité Paris Descartes/Paris V , Sorbonne Paris Cité , Paris, France ; INSERM; U970 ; Paris, France ; Paris-Cardiovascular Research Center (PARCC) ; Paris, France ; Service d'Immunologie Biologique; Hôpital Européen Georges Pompidou (HEGP); AP-HP ; Paris, France.
Laurence ZitvogelGustave Roussy Cancer Campus ; Villejuif, France ; INSERM; U1015; CICBT507 ; Villejuif, France.
Guido KroemerINSERM; U1138 ; Paris, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Centre de Recherche des Cordeliers ; Paris, France ; Université Pierre et Marie Curie/Paris VI ; Paris, France ; Université Paris Descartes/Paris V , Sorbonne Paris Cité , Paris, France ; Pôle de Biologie; Hôpital Européen Georges Pompidou; AP-HP ; Paris, France ; Metabolomics and Cell Biology Platforms; Gustave Roussy Cancer Campus ; Villejuif, France.
Lorenzo GalluzziGustave Roussy Cancer Campus ; Villejuif, France ; INSERM; U1138 ; Paris, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Centre de Recherche des Cordeliers ; Paris, France ; Université Pierre et Marie Curie/Paris VI ; Paris, France ; Université Paris Descartes/Paris V , Sorbonne Paris Cité , Paris, France.
Sorbonne Université · FRCharles University · CZSorbonne Paris Cité · FRWeatherford College · USCentre de Recherche des Cordeliers · FRConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESInserm · FRInstitut Gustave Roussy · FRUniversité Paris Cité · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
One particular paradigm of anticancer immunotherapy relies on the administration of (potentially) tumor-reactive immune effector cells. Generally, these cells are obtained from autologous peripheral blood lymphocytes (PBLs)
Indexed as
checkpoint blockerschimeric antigen receptorGM-CSFTCRTLR agoniststumor-associated antigens
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.